Martínez M A, Pinto M E, Giglio M S, Pommier J, Muñoz L M
Departamento de Preclínicos, Facultad de Medicina, Universidad de Chile.
Rev Med Chil. 1992 Nov;120(11):1267-72.
One hundred thirty two strains of acinetobacter isolated between october 1989 and march 1991 at the San Juan de Dios Hospital, Santiago de Chile were included in this study. One hundred twelve isolates were obtained from patients and 20 from the hospital environment. Among the 112 clinical isolates, 108 (96.4%) were identified according to the new classification proposed by Bouvet and Grimont in 1986 as A. baumannii, and four as acinetobacter genospecies 3. The 20 strains obtained from the hospital environment corresponded to A baumannii. No differences in the activities of the antimicrobial agents were found between clinical and environmental strains of A baumannii. Imipenem was the most active antimicrobial drug against A baumannii followed in descending order by sulbactam ampicillin and ceftazidime. The other antimicrobials tested showed poor activity against these strains as revealed for the MICs 50 and 90 in the resistance range.
1989年10月至1991年3月期间,从智利圣地亚哥圣胡安·迪奥斯医院分离出的132株不动杆菌纳入了本研究。其中112株分离自患者,20株来自医院环境。在112株临床分离株中,根据Bouvet和Grimont于1986年提出的新分类法,108株(96.4%)被鉴定为鲍曼不动杆菌,4株为不动杆菌基因种3。从医院环境中获得的20株菌株均为鲍曼不动杆菌。鲍曼不动杆菌的临床菌株和环境菌株之间未发现抗菌药物活性存在差异。亚胺培南是针对鲍曼不动杆菌活性最强的抗菌药物,其次依次为舒巴坦氨苄西林和头孢他啶。其他测试的抗菌药物对这些菌株的活性较差,如在耐药范围内的MIC50和MIC90所示。